Cancer
RASolute
Pancreatic Cancer
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Contact Research Team:
[email protected]
Site principal investigator:
Marc Roth, MD
Learn more about this study:
NCT07252232